Sutton, United Kingdom

Lynn Margaret Bjerke

USPTO Granted Patents = 9 


Average Co-Inventor Count = 5.1

ph-index = 1


Location History:

  • Sutton, GB (2011 - 2014)
  • London, GB (2011 - 2014)

Company Filing History:


Years Active: 2011-2014

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Lynn Margaret Bjerke: Innovator in Genetic Modulation

Introduction

Lynn Margaret Bjerke is a notable inventor based in Sutton, GB. She has made significant contributions to the field of genetic modulation, holding a total of nine patents. Her work focuses on identifying therapeutic targets for disorders associated with defective pathways in human genes.

Latest Patents

Among her latest patents are two groundbreaking inventions. The first patent, titled "CDK9 as modifier of the IGF pathway and methods of use," identifies human CDK9 genes as modulators of the IGF pathway. This discovery positions CDK9 as a therapeutic target for disorders linked to defective IGF function. The second patent, "EEF2K as modifiers of the PTEN/AKT pathway and methods of use," highlights human EEF2K genes as modulators of the PTEN/AKT pathway. This invention also aims to provide methods for identifying agents that can modulate the activity of EEF2K, offering potential therapeutic avenues for disorders associated with defective PTEN/AKT function.

Career Highlights

Lynn currently works at Exelixis, Inc., where she continues to advance her research in genetic modulation. Her innovative work has positioned her as a key figure in the field, contributing to the understanding of complex genetic pathways.

Collaborations

Lynn collaborates with esteemed colleagues, including Timothy S Heuer and Lori Friedman, who contribute to her research endeavors and enhance the impact of her work.

Conclusion

Lynn Margaret Bjerke's contributions to genetic modulation through her patents and collaborations underscore her importance in the field. Her innovative research continues to pave the way for new therapeutic strategies targeting critical genetic pathways.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…